Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates

Epigenetics

Volumn 10, Issue 5, 2015, Pages 361-372

  Gurnot, Cécile ^a,b   Martin Subero, Ignacio ^c   Mah, Sarah M ^d   Weikum, Whitney ^d   Goodman, Sarah J ^d   Brain, Ursula ^d   Werker, Janet F ^e,f   Kobor, Michael S ^d,e,f   Esteller, Manel ^c,g,h   Oberlander, Tim F ^d,e   Hensch, Takao K ^a,b,f  

^a HARVARD UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CANADIAN INSTITUTE FOR ADVANCED RESEARCH   (Canada)

^g BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

CYP2E1; Depression; Neonatal health; Pregnancy; Serotonin reuptake inhibitor (SRI) antidepressants

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOCHROME P450 2E1; FLUOXETINE; GENOMIC DNA; NORFLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; CLINICAL ARTICLE; CPG ISLAND; CYTOCHROME P450 2E1 GENE; DNA EXTRACTION; DNA METHYLATION; DNA MICROARRAY; FEMALE; GENE; HEAD CIRCUMFERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; NEWBORN; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PUERPERAL DEPRESSION; PYROSEQUENCING; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; VALIDATION PROCESS; BIRTH; COHORT ANALYSIS; CYTOLOGY; DRUG EFFECTS; LEUKOCYTE; MALE; METABOLISM; MOOD DISORDERS; PREGNANCY; PRENATAL EXPOSURE; UMBILICAL CORD;

ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; CPG ISLANDS; CYTOCHROME P-450 CYP2E1; DNA METHYLATION; FEMALE; HUMANS; INFANT, NEWBORN; LEUKOCYTES; MALE; MOOD DISORDERS; PARTURITION; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS; UMBILICAL CORD;

EID: 84951271383     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2015.1026031     Document Type: Article

References (85)

1. Hanley GE, Oberlander TF. Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a “social teratogen” or moderator of developmental risk? Birth Defects Res A Clin Mol Teratol 2012; 94:651-9; PMID:22733632
2. Talge NM, Neal C, Glover V. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psychiat 2007; 48:245-61; PMID:17355398; http://dx.doi.org/10.1111/j.1469-7610.2006.01714.x
3. Steer RA, Scholl TO, Hediger ML, Fischer RL. Selfreported depression and negative pregnancy outcomes. J Clin Epidemiol 1992; 45:1093-9; PMID:1474405; http://dx.doi.org/10.1016/0895-4356(92)90149-H
4. Pilowsky DJ, Wickramaratne P, Talati A, Tang M, Hughes CW, Garber J, Malloy E, King C, Cerda G, Sood AB, et al. Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiat 2008; 165:1136-47; PMID:18558646; http://dx.doi.org/10.1176/appi.ajp.2008.07081286
5. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiat 2010; 67:1012-24; PMID:20921117; http://dx.doi.org/10.1001/archgenpsychiatry.2010.111
6. Field T, Diego M, Hernandez-Reif M, Figueiredo B, Schanberg S, Kuhn C, Deeds O, Contogeorgos J, Ascencio A. Chronic prenatal depression and neonatal outcome. The Int J Neurosci 2008; 118:95-103; PMID:18041608; http://dx.doi.org/10.1080/00207450601042144
7. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006; 29:445-55; PMID:17138297; http://dx.doi.org/10.1016/j.infbeh.2006.03.003
8. Diego MA, Field T, Hernandez-Reif M, Schanberg S, Kuhn C, Gonzalez-Quintero VH. Prenatal depression restricts fetal growth. Early Hum Dev 2009; 85:65-70; PMID:18723301; http://dx.doi.org/10.1016/j.earlhumdev.2008.07.002
9. Popa D, Lena C, Alexandre C, Adrien J. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J Neurosci 2008; 28:3546-54; PMID:18385313; http://dx.doi.org/10.1523/JNEUROSCI.4006-07.2008
10. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population- based health data. Birth Defects Res B, Dev Reprod Ttoxicol 2008; 83:68-76; PMID:18293409; http://dx.doi.org/10.1002/bdrb.20144
11. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008; 3:e2782; PMID:18716672; http://dx.doi.org/10.1371/journal.pone.0002782
12. Lisboa SF, Oliveira PE, Costa LC, Venancio EJ, Moreira EG. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007; 80:49-56; PMID:17519559; http://dx.doi.org/10.1159/000103097
13. Grzeskowiak LE, Gilbert AL, Morrison JL. Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J Clin Psychopharmacol 2012; 32:615-21; PMID:22926594; http://dx.doi.org/10.1097/JCP.0b013e31826686bc
14. Grzeskowiak LE, Gilbert AL, Morrison JL. Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues. Drug saf 2011; 34:1027-48; PMID:21981432; http://dx.doi.org/10.2165/11593130-000000000-00000
15. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005; 19:623-33; PMID:15984897; http://dx.doi.org/10.2165/00023210-200519070-00004
16. Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reproductive toxicology (Elmsford, NY) 2010; 30:249-60; PMID:20447455
17. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Orai- chi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Def Res B Dev Reprod Toxicol 2007; 80:18-27; PMID:17187388; http://dx.doi.org/10.1002/bdrb.20099
18. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early- life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004; 306:879-81; PMID:15514160;http://dx.doi.org/10.1126/science.1101678
19. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS drugs 2009; 23:493-509; PMID:19480468; http://dx.doi.org/10.2165/00023210-200923060-00004
20. Weikum WM, Oberlander TF, Hensch TK, Werker JF. Prenatal exposure to antidepressants and depressed maternal mood alter trajectory ofinfant speech perception. Proc Natl Acad Sci USA 2012; 109 Suppl 2:17221-7; PMID:23045665; http://dx.doi.org/10.1073/pnas.1121263109
21. Shea AK, Oberlander TF, Rurak D. Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors. CanJ Psychiatry 2012; 57:523-9; PMID:23073029
22. Soubry A, Murphy S, Huang Z, Murtha A, Schildkraut J, Jirtle R, Wang F, Kurtzberg J, Demark-Wahnefried W, Forman M, et al. The effects ofdepression and use ofanti- depressive medicines during pregnancy on the methyla- tion status of the IGF2 imprinted control regions in the offspring. Clin Epigenet 2011; 3:2; PMID:22414206; http://dx.doi.org/10.1186/1868-7083-3-2
23. Jensen Pena C, Monk C, Champagne FA. Epigenetic effects of prenatal stress on 11beta-hydroxysteroid dehydrogenase-2 in the placenta and fetal brain. PLoS One 2012; 7:e39791; PMID:22761903; http://dx.doi.org/10.1371/journal.pone.0039791
24. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epige- netics 2008; 3:97-106; PMID:18536531; http://dx.doi.org/10.4161/epi.3.2.6034
25. Mulligan CJ, D’Errico NC, Stees J, Hughes DA. Meth- ylation changes at NR3C1 in newborns associate with maternal prenatal stress exposure and newborn birth weight. Epigenetics 2012; 7:853-7; PMID:22810058; http://dx.doi.org/10.4161/epi.21180
26. Mueller BR, Bale TL. Sex-specific programming of offspring emotionality after stress early in pregnancy. J Neurosci 2008; 28:9055-65; PMID:18768700; http://dx.doi.org/10.1523/JNEUROSCI.1424-08.2008
27. Devlin AM, Brain U, Austin J, Oberlander TF. Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS One 2010; 5:e12201; PMID:20808944
28. Benton CS, Miller BH, Skwerer S, Suzuki O, Schultz LE, Cameron MD, Marron JS, Pletcher MT, Wiltshire T. Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains. Psychopharmacology 2012; 221:297-315; PMID:22113448; http://dx.doi.org/10.1007/s00213-011-2574-z
29. Cassel S, Carouge D, Gensburger C, Anglard P, Bur- gun C, Dietrich JB, Aunis D, Zwiller J. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol Pharmacol 2006; 70:487-92; PMID:16670375; http://dx.doi.org/10.1124/mol.106.022301
30. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010; 329:1537-41; PMID:20847275; http://dx.doi.org/10.1126/science.1193692
31. Melas PA, Rogdaki M, Lennartsson A, Bjork K, Qi H, Witasp A, Werme M, Wegener G, Mathe AA, Sven- ningsson P, et al. Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J neuropsychopharma- col 2012; 15:669-79; PMID:21682946
32. Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007; 62:55-64; PMID:16945350; http://dx.doi.org/10.1016/j.biopsych.2006.06.036
33. Covington HE, III, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, Fass DM, Renthal W, Rush AJ, III, Wu EY, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009; 29:11451-60; PMID:19759294; http://dx.doi.org/10.1523/JNEUROSCI.1758-09.2009
34. LaPlant Q, Vialou V, Covington HE, III, Dumitriu D, Feng J, Warren BL, Maze I, Dietz DM, Watts EL, Iniguez SD, et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci 2010; 13:1137-43; PMID:20729844; http://dx.doi.org/10.1038/nn.2619
35. Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T, Suzuki T, Miyata N, Watanabe Y. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011; 69:359-72; PMID:21262472; http://dx.doi.org/10.1016/j.neuron.2010.12.023.
36. LaPlant Q, Vialou V, Covington HE, III, Dumitriu Feng J, Warren BL, Maze I, Dietz DM, Watts EL, Iniguez SD, et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci 2010; 13:1137-43; PMID:20729844; http://dx.doi.org/10.1038/nn.2619
37. Covington HE, III, Maze I, Sun H, Bomze HM, DeMaio KD, Wu EY, Dietz DM, Lobo MK, Ghose S, Mouzon E, et al. A role for repressive histone methyla- tion in cocaine-induced vulnerability to stress. Neuron 2011; 71:656-70; PMID:21867882; http://dx.doi.org/10.1016/j.neuron.2011.06.007
38. Jiang Y, Jakovcevski M, Bharadwaj R, Connor C, Schroeder FA, Lin CL, Straubhaar J, Martin G, Akbar- ian S. Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B. J Neurosci 2010; 30:7152-67; PMID:20505083; http://dx.doi.org/10.1523/JNEUR0SCI.1314-10.2010
39. Non AL, Binder AM, Kubzansky LD, Michels KB. Genome-wide DNA methylation in neonates exposed to maternal depression, anxiety, or SSRI medication during pregnancy. Epigenetics 2014; 9(7):964-72; PMID:24751725;http://dx.doi.org/10.4161/epi.28853
40. Schroeder JW, Smith AK, Brennan PA, Conneely KN, Kilaru V, Knight BT, Newport DJ, Cubells JF, Stowe ZN. DNA methylation in neonates born to women receiving psychiatric care. Epigenetics 2012; 7:409-14; PMID:22419064; http://dx.doi.org/10.4161/epi.19551
41. Yau JL, Noble J, Chapman KE, Seckl JR. Differential regulation ofvariant glucocorticoid receptor mRNAs in the rat hippocampus by the antidepressant fluoxetine. Brain Res Mol Brain Res 2004; 129:189-92; PMID:15469896; http://dx.doi.org/10.1016/j.molbrainres.2004.06.033
42. Maksymchuk O, Chashchyn M. The impact ofpsycho- genic stressors on oxidative stress markers and patterns of CYP2E1 expression in mice liver. Pathophysiology 2012; 19:215-9; PMID:22874632
43. Lam LL, Emberly E, Fraser HB, Neumann SM, Chen Miller GE, Kobor MS. Factors underlying variable DNA methylation in a human community cohort. Proc Natl Acad Sci USA 2012; 109 Suppl 2:17253-60; PMID:23045638; http://dx.doi.org/10.1073/pnas.1121249109
44. Koh KH, Xie H, Yu AM, Jeong H. Altered cytochrome P450 expression in mice during pregnancy. Drug Metab Dispos 2011; 39:165-9; PMID:20971892; http://dx.doi.org/10.1124/dmd.110.035790
45. He XJ, Ejiri N, Nakayama H, Doi K. Effects of pregnancy on CYPs protein expression in rat liver. Exp Mol Pathol 2005; 78:64-70; PMID:15596063; http://dx.doi.org/10.1016/j.yexmp.2004.08.011
46. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005; 569:101-10; PMID:15603755; http://dx.doi.org/10.1016/j.mrfmmm.2004.04.021
47. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-9; PMID:8477556;http://dx.doi.org/10.1038/clpt.1993.43
48. Newton SS, Duman RS. Chromatin remodeling: a novel mechanism of psychotropic drug action. Mol Pharmacol 2006; 70:440-3; PMID:16728645; http://dx.doi.org/10.1124/mol.106.027078
49. Hyman SE. Even chromatin gets the blues. Nat Neuro- sci 2006; 9:465-6; PMID:16568101
50. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9:519-25; PMID:16501568; http://dx.doi.org/10.1038/nn1659
51. Maccani MA, Padbury JF, Marsit CJ. miR-16 and miR-21 expression in the placenta is associated with fetal growth. PLoS One 2011; 6:e21210; PMID:21698265
52. Filiberto AC, Maccani MA, Koestler D, Wilhelm- Benartzi C, Avissar-Whiting M, Banister CE, Gagne LA, Marsit CJ. Birth weight is associated with DNA promoter methylation ofthe glucocorticoid receptor in human placenta. Epigenetics 2011; 6:566-72; PMID:21521940; http://dx.doi.org/10.4161/epi.6.5.15236
53. Ferreira JC, Choufani S, Grafodatskaya D, Butcher DT, Zhao C, Chitayat D, Shuman C, Kingdom J, Keating S, Weksberg R. WNT2 promoter methylation in human placenta is associated with low birth weight percentile in the neonate. Epigenetics 2011; 6:440-9; PMID:21474991; http://dx.doi.org/10.4161/epi.6.4.14554
54. Hoyo C, Fortner K, Murtha AP, Schildkraut JM, Soubry A, Demark-Wahnefried W, Jirtle RL, Kurtz- berg J, Forman MR, Overcash F, et al. Association of cord blood methylation fractions at imprinted insulinlike growth factor 2 (IGF2), plasma IGF2, and birth weight. Cancer Causes Control 2012; 23:635-45; PMID:22392079; http://dx.doi.org/10.1007/s10552-012-9932-y
55. Sasaki S, Sata F, Katoh S, Saijo Y, Nakajima S, Wash- ino N, Konishi K, Ban S, Ishizuka M, Kishi R. Adverse birth outcomes associated with maternal smoking and polymorphisms in the N-Nitrosamine-metabolizing enzyme genes NQO1 and CYP2E1. Am J Epidemiol 2008; 167:719-26; PMID:18218609; http://dx.doi.org/10.1093/aje/kwm360
56. Chen D, Hu Y, Yang F, Li Z, Wu B, Fang Z, Li J, Wang L. Cytochrome P450 gene polymorphisms and risk of low birth weight. Genet Epidemiol 2005; 28:368-75; PMID:15712341; http://dx.doi.org/10.1002/gepi.20067
57. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol 2009; 83:519-48; PMID:19448996; http://dx.doi.org/10.1007/s00204-009-0432-0
58. Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991; 39:275-80; PMID:2005876
59. O’Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Therapeut 1994; 56:359-67; PMID:7955797; http://dx.doi.org/10.1038/clpt.1994.150
60. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003; 55:77-85; PMID:12534643; http://dx.doi.org/10.1046/j.1365-2125.2003.01731.x
61. Dong ZG, Hong JY, Ma QA, Li DC, Bullock J, Gonzalez FJ, Park SS, Gelboin HV, Yang CS. Mechanism ofinduction ofcytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Arch Biochem Biophys 1988; 263:29-35; PMID:3285794; http://dx.doi.org/10.1016/0003-9861(88)90610-8
62. Butura A, Nilsson K, Morgan K, Morgan TR, French SW, Johansson I, Schuppe-Koistinen I, Ingelman- Sundberg M. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol 2009; 50:572-83; PMID:19157621; http://dx.doi.org/10.1016/j.jhep.2008.10.020
63. Kaut O, Schmitt I, Wullner U. Genome-scale methyla- tion analysis of Parkinson’s disease patients’ brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 2012; 13:87-91; PMID:22238121; http://dx.doi.org/10.1007/s10048-011-0308-3
64. Chevrier C, Perret C, Bahuau M, Nelva A, Herman C, Francannet C, Robert-Gnansia E, Cordier S. Fetal and maternal CYP2E1 genotypes and the risk of nonsyn- dromic oral clefts. Am J Med Genet A 2007; 143A:1382-5; PMID:17506098; http://dx.doi.org/10.1002/ajmg.a.31779
65. Botto F, Seree E, el Khyari S, de Sousa G, Massacrier A, Placidi M, Cau P, Pellet W, Rahmani R, Barra Y. Tissue-specific expression and methylation of the human CYP2E1 gene. Biochem Pharmacol 1994; 48:1095-103; PMID:7945402; http://dx.doi.org/10.1016/0006-2952(94)90145-7
66. Botto F, Seree E, el Khyari S, Cau P, Henric A, De Meo M, Bergeron P, Barra Y. Hypomethylation and hypoexpression of human CYP2E1 gene in lung tumors. Biochem Biophys Res Commun 1994; 205:1086-92; PMID:7802636; http://dx.doi.org/10.1006/bbrc.1994.2777
67. Jones SM, Boobis AR, Moore GE, Stanier PM. Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. Biochem Pharmacol 1992; 43:1876-9; PMID:1575782; http://dx.doi.org/10.1016/0006-2952(92)90726-Y
68. Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. European journal of biochemistry/FEBS 1996; 238:476-83; PMID:8681961
69. Botto F, Seree E, el Khyari S, Cau P, Henric A, De Meo M, Bergeron P, Barra Y. Hypomethylation and hypoexpression of human CYP2E1 gene in lung tumors. Biochem Biophys Res Commun 1994; 205:1086-92; PMID:7802636; http://dx.doi.org/10.1006/bbrc.1994.2777
70. Martis S, Mei H, Vijzelaar R, Edelmann L, Desnick RJ, Scott SA. Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. Pharmaco- genomics J 2013; 13:558-66; PMID:23164804; http://dx.doi.org/10.1038/tpj.2012.48
71. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M. Structural and functional characterization of the 5’- flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 1999; 263:286-93; PMID:10491286; http://dx.doi.org/10.1006/bbrc.1999.1362
72. Das P, Shaik AP, Bammidi VK. Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia. Leuk Lymphoma 2009; 50:1345-51; PMID:19811334; http://dx.doi.org/10.1080/10428190903003236
73. Cho HJ, Eom HS, Kim HJ, Kim IS, Lee GW, Kong SY. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2010; 198:40-6; PMID:20303013; http://dx.doi.org/10.1016/j_cancergencyto.2009.12.004
74. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadow- sky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer’s disease. The Tacrine Study Group. JAMA 1992; 268:2523-9; PMID:1404819; http://dx.doi.org/10.1001/jama.1992.03490180055026
75. Kawas CH. Clinical practice. Early Alzheimer’s disease. N Eng J Med 2003; 349:1056-63; PMID:12968090; http://dx.doi.org/10.1056/NEJMcp022295
76. Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer’s disease. Curr Drug Metabol 2008; 9:332-5; PMID:18473751; http://dx.doi.org/10.2174/138920008784220619
77. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, et al. Incorporation of phar- macogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metabol 2014; 15:209-17; PMID:24479687; http://dx.doi.org/10.2174/1389200215666140130124910
78. Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004; 26:685-7; PMID:15570195; http://dx.doi.org/10.1097/00007691-200412000-00016
79. Jones MJ, Fejes AP, Kobor MS. DNA methylation, genotype and gene expression: who is driving and who is along for the ride? Genome Biol 2013; 14:126; PMID:23899167; http://dx.doi.org/10.1186/gb-2013-14-7-126
80. Simpson KL, Weaver KJ, de Villers-Sidani E, Lu JY, Cai Z, Pang Y, Rodriguez-Porcel F, Paul IA, Merzenich M, Lin RC. Perinatal antidepressant exposure alters cortical network function in rodents. Proc Natl Acad Sci U S A 2011; 108:18465-70; PMID:22025710; http://dx.doi.org/10.1073/pnas.1109353108
81. Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics 2014;133:e1241-8; PMID:24733881; http://dx.doi.org/10.1542/peds.2013-3406
82. Clements CC, Castro VM, Blumenthal SR, Rosenfield HR, Murphy SN, Fava M, Erb JL, Churchill SE, Kai- mal AJ, Doyle AE, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry 2014; in press; PMID:25155880
83. Hamilton M. A rating scale for depression. J Neurol, neurosurgeryPsychiatry 1960; 23:56-62.
84. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (Oxford, England) 2003; 19:185-93.
85. Storey JD, Dai JY, Leek JT. The optimal discovery procedure for large-scale significance testing, with applications to comparative microarray experiments. Biostatistics (Oxford, England) 2007; 8:414-32.